Summary
The pharmacokinetics of naproxen have been examined in 13 elderly patients (mean age 84.2 years) and in 9 younger patients (mean age 53.9 years) at the end of a 21 day course of therapy with naproxen 500 mg b.d. The mean pre-dose concentration on days 19, 20 and 21 was significantly higher in the elderly patients than in the controls (60.1 vs. 43.3 µ g · ml−1). The AUC (0–24) was significantly higher in the elderly subjects only when normalized for body weight (9.1 vs. 5.4 µg·ml−1·h kg−1 p⩽0.02). The AUC was significantly higher in the elderly group compared to the control group also in the normalized form. The apparent clearance of naproxen was reduced in the elderly compared to the control patients (315 vs. 628 ml·h−1). The percentage protein binding of naproxen was the same in both groups (99.8%) but the free concentration of naproxen was significantly higher in the elderly patients than in the control patients (141 vs. 89.8 ng·ml−1). Although there was no excess of side effects in the elderly patients it is suggested that when naproxen is given to elderly patients, therapy should be started at the lower end of the dosage range.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Advenier C Roux, Gobert C, Massias P, Varoquaux D, Flouvat B (1983) Pharmacokinetics of ketoprofen in the elderly. Br J Clin Pharmacol 16: 65–70
Campbell AJ, Ferry DG, Edwards IR (1985) Pharmacokinetic projections for isoxicam and piroxicam in old and young subjects. Br J Rheumatol 24: 176–178
Greenblatt DJ, Matlis R, Scavone JM, Blyden GT, Harmataz JS, Shader RI (1985) Oxaprozin pharmacokinetics in the elderly. Br J Clin Pharmacol 19: 373–378
Hamdy RC, Murnane B, Perera N, Woodcock K, Koch IM (1982) The pharmacokinetics of benoxaprofen in elderly subjects. Eur J Rheumatol Inflamm 5: 69–75
Janke PG, Diggins JB, Currie WJC, Dasgupta PK, Glick EN, Sheikh HA, Shujja-Ud-Din (1984) A multicentre study of sulindac versus naproxen in the treatment of elderly osteoarthritic patients. Pharmatherapeutics 10: 663–667
Pathy MSJ (1982) Osteoarthritis and non-steroidal anti-inflammatory drugs: a multi centre comparative study. Curr Med Res Opin 7: [Suppl 1] 41–52
Richardson CJ, Blocka KLN, Ross SG, Verbeeck RK (1985) Effects of age and sex on piroxicam disposition. Clin Pharmacol Ther 37: 13–18
Ritch AES, Perera WNR, Jones CJ (1982) Pharmacokinetics of azapropazone in the elderly. Br J Clin Pharmacol 14: 116–119
Rooney L, Kendall MJ, Main A, Hosie J, John VA (1985) Pharmacokinetics of pirprofen in young volunteers and elderly patients. Eur J Clin Pharmacol 29: 73–77
Somerville K, Faulkner G, Langman M (1986) Non-steroidal anti-inflammatory drugs and bleeding peptic ulcer. Lancet i: 462–464
Taggart HM, Alderice JM (1982) Fatal cholestatic jaundice in elderly patients taking benoxaprofen. Br Med J 284: 1372
Traeger A, Kunze M, Stein G, Ankermann H (1973) Zur Pharmacokinetik von Indomethazin bei alten Menschen. Z Alternsforsch 27: 151–155
Upton RA, Buskin JN, Williams RL, Halford NHG, Riegelman S (1980) Negligible excretion of unchanged ketoprofen, naproxen and probenecid in urine. J Pharm Sci 69: 1254–1257
Upton RA, Williams RL, Kelly J, Jones RM (1984) Naproxen Pharmacokinetics in the elderly. Br J Clin Pharmacol 18: 207–214
Woolf AD, Rogers JH, Bradbrook ID, Corless D (1983) Pharmacokinetic observations on piroxicam in young adult, middle aged and elderly patients. Br J Clin Pharmacol 16: 433–437
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
McVerry, R.M., Lethbridge, J., Martin, N. et al. Pharmacokinetics of naproxen in elderly patients. Eur J Clin Pharmacol 31, 463–468 (1986). https://doi.org/10.1007/BF00613525
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00613525